Heart BMJ

MARCH 22, 2024

Immune-mediated inflammatory diseases (IMIDs) are recognised risk factors for accelerated atherosclerotic cardiovascular disease (CVD), particularly in younger individuals and women who lack traditional CVD risk factors.

Plaque 40

Plaque Atherosclerosis Risk Factors Angina 40

Circulation

NOVEMBER 11, 2024

Background:Ischemic heart disease (IHD) is a prevalent cardiovascular disease (CVD) associated with high morbidity and mortality. Frailty and CVD are often interrelated, affecting disease and treatment outcomes. Circulation, Volume 150, Issue Suppl_1 , Page A4147397-A4147397, November 12, 2024.

Heart Disease 40

Heart Disease Hospital Inpatient Outcomes 40

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

Takotsubo is a sudden event, not one with crescendo angina. Hospital Course The patient was taken emergently to the cath lab which did not reveal any significant coronary artery disease, but she was noted to have reduced EF consistent with Takotsubo cardiomyopathy. I need to innoculate you against the subsequent opinions below.

Plaque 52

Plaque Chest Pain Thrombosis Stenosis 52

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

DAIC

MAY 14, 2024

Within the complex umbrella of cardiovascular disease, CAD is a type of heart disease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart. Use Heart to Act on Angina. For more information: www.gehealthcare.com References: 1 World Health Federation.

Coronary Artery Disease 111

Coronary Artery Disease Interventional Cardiology Innovation Physiology 111

Heart BMJ

JUNE 25, 2024

Background We aimed to investigate the effectiveness of fixed-dose combination therapy (polypill) for primary and secondary prevention of major cardiovascular diseases in a typical rural setting. The Cox regression model, with shared frailty, was used to account for clustering effect. Trial registration number NCT03459560.

Cardiovascular Disease 59

Cardiovascular Disease Myocardial Infarction Pharmacology Angina 59

DAIC

APRIL 2, 2024

For individuals with cardiovascular diseases, the limit is even lower at 1,500 mg/day, according to guideline recommendations from the ACC and the American Heart Association. Yet, adhering to a low sodium diet remains challenging even for individuals with cardiovascular disease who have a strong incentive to adhere.”

Heart Disease 105

Heart Disease Cardiovascular Disease Diet Coronary Artery Disease 105

Journal of the American Heart Association

FEBRUARY 26, 2024

BackgroundThere are few data on sex differences in the association between schizophrenia and the development of cardiovascular disease (CVD). The primary end point is defined as a composite end point that includes myocardial infarction, angina pectoris, stroke, heart failure, atrial fibrillation, and pulmonary thromboembolism.

Cardiovascular Disease 76

Cardiovascular Disease Angina Myocardial Infarction Heart Failure 76

Circulation

FEBRUARY 12, 2024

We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).METHODS:A years, type 2 diabetes duration of 4.0±2.7

Diabetes 80

Diabetes Outcomes Myocardial Infarction Heart Failure 80

DAIC

APRIL 5, 2024

a company that has developed the Reducer System, a novel product focused on symptom relief of refractory angina. The acquisition of Shockwave and its leading IVL technology provides a unique opportunity to accelerate our impact in cardiovascular intervention and drive greater value for patients, shareholders and health systems.”

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

Introduction Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up.

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Drug Costs Myocardial Infarction 45

Circulation

NOVEMBER 11, 2024

Introduction:Historically, Middle-Eastern (ME) immigrants have been aggregated with Non-Hispanic White (NHW) individuals, masking disparities in cardiovascular diseases (CVD). Circulation, Volume 150, Issue Suppl_1 , Page A4139303-A4139303, November 12, 2024.

Risk Factors 40

Risk Factors Cardiovascular Disease Cholesterol Hypertension 40

Circulation

NOVEMBER 11, 2024

Background:Among patients presenting with atherosclerotic cardiovascular disease (ASCVD), the proportion of young individuals has increased in recent years. Circulation, Volume 150, Issue Suppl_1 , Page A4125581-A4125581, November 12, 2024.

Cardiovascular Disease 40

Cardiovascular Disease Heart Attack Heart attacks Angina 40

Cardiometabolic Health Congress

MAY 10, 2024

The American Heart Association’s scientific statement, “Psychological Health, Well-Being, and the Mind-Heart-Body Connection,” emphasizes the need to evaluate and address psychological health in patients with or at risk for cardiovascular disease (CVD). Combining behavioral and pharmacological treatment is most effective.

Coronary Artery Disease 59

Coronary Artery Disease Obesity Chest Pain Ischemia 59

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. in the medical therapy group.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

DAIC

MARCH 25, 2024

BE ACTIVE—about physical activity and how physical activity is enhanced in patients looking at financial incentivization as well as gamification, and what that does for physical activity with regards to patients who have MI and a high risk for cardiovascular disease.

Education 59

Education Cardiogenic Shock Heart Failure Plaque 59

MIBHS

DECEMBER 13, 2024

Erectile dysfunction (ED) is a common concern among men, especially those dealing with cardiovascular disease. The connection between heart health, vascular risk factors, and sexual function is well-documented, with poor cardiovascular health often leading to or exacerbating erectile issues.

Coronary Artery Bypass Graft 52

Coronary Artery Bypass Graft Diet Heart Disease Risk Factors 52

Dr. Anish Koka

JANUARY 18, 2023

Those of us hoping that super low LDL levels would abolish cardiovascular disease were pretty disappointed with the results of the trial published in 2017. While the drug destroyed LDL levels in blood compared to the control arm, it didn’t come anywhere close to abolishing cardiovascular disease.

Document 52

Document Academic Heart Attack Heart attacks 52

Frontiers in Cardiovascular Medicine

DECEMBER 20, 2024

BackgroundCardiovascular disease(CVD) remains a significant global challenge. Asthma, which is characterized by airway hyperresponsiveness and reversible and limited airflow, plays an important role in cardiovascular diseases. CVD included stroke, congestive heart failure, coronary heart disease, and angina.

Cardiovascular Disease 52

Cardiovascular Disease Heart Failure BMI Angina 52

Frontiers in Cardiovascular Medicine

NOVEMBER 21, 2024

This study examines the association between eGFR and cardiovascular disease (CVD) risk in a representative cohort of the US adult population.MethodsA cross-sectional analysis was conducted using data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. ml/min/1.73 m².

Cardiovascular Disease 52

Cardiovascular Disease Myocardial Infarction Kidney Disease Angina 52

Frontiers in Cardiovascular Medicine

JANUARY 8, 2025

ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovascular diseases, cerebrovascular diseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions.

Cerebrovascular Disease 52

Cerebrovascular Disease Cardiovascular Disease Myocardial Infarction Angina 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Additionally, the ongoing ORBITA-2 trial examines the use of percutaneous coronary intervention (PCI) for stable angina, offering valuable insights into procedural benefits and outcomes​. The trial highlights the importance of reevaluating and optimizing thrombolytic therapies for better patient outcomes.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59